Biochemical activity of RAGs is impeded by Dolutegravir, an HIV integrase inhibitor

被引:12
作者
Nilavar, Namrata M. [1 ]
Paranjape, Amita M. [1 ]
Raghavan, Sathees C. [1 ]
机构
[1] Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India
关键词
NON-B-DNA; MAJOR BREAKPOINT REGION; V(D)J RECOMBINATION; CHROMOSOMAL TRANSLOCATIONS; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; MECHANISM; RALTEGRAVIR; IDENTIFICATION; PATHOGENESIS;
D O I
10.1038/s41420-020-0281-4
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
HIV is a retrovirus that infects CD4(+)T lymphocytes in human beings and causes immunodeficiency. In the recent years, various therapies have been developed against HIV, including targeting the HIV specific protein, integrase, responsible for integration of HIV cDNA into host DNA. Although, integrase is specific to HIV, it has functional and structural similarity with RAG1, one of the partner proteins associated with V(D)J recombination, a process by which immune diversity is generated in humans. Currently, there are three HIV integrase inhibitors: Elvitegravir, Dolutegravir, and Raltegravir, in the market which have been approved by the FDA (USA). All three drugs are used in anti-retroviral therapy (ART). Previously, we showed that amongst the HIV inhibitors, Elvitegravir could significantly decrease B cell maturation in vivo and inhibit the physiological activities of RAGs in vitro, unlike Raltegravir. In the present study, we address the effect of second-generation integrase inhibitor, Dolutegravir on RAG activities. Binding and nicking studies showed that, Dolutegravir could decrease the binding efficiency of RAG1 domains and cleavage on DNA substrates, but not as considerably as Elvitegravir. Thus, we show that although the integrase inhibitors such as Elvitegravir show an affinity towards RAG1, the newer molecules may have lesser side-effects.
引用
收藏
页数:8
相关论文
共 51 条
  • [1] Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study
    Akil, Bisher
    Blick, Gary
    Hagins, Debbie P.
    Ramgopal, Moti N.
    Richmond, Gary J.
    Samuel, Rafik M.
    Givens, Naomi
    Vavro, Cindy
    Song, Ivy H.
    Wynne, Brian
    Ait-Khaled, Mounir
    [J]. ANTIVIRAL THERAPY, 2015, 20 (03) : 343 - 348
  • [2] HIV drug resistance against strand transfer integrase inhibitors
    Anstett, Kaitlin
    Brenner, Bluma
    Mesplede, Thibault
    Wainberg, Mark A.
    [J]. RETROVIROLOGY, 2017, 14
  • [3] Identification of two topologically independent domains in RAG1 and their role in macromolecular interactions relevant to V(D)J recombination
    Arbuckle, JL
    Fauss, LJ
    Simpson, R
    Ptaszek, LM
    Rodgers, KK
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (40) : 37093 - 37101
  • [4] Molecular mechanisms in retrovirus DNA integration
    Asante-Appiah, E
    Skalka, AM
    [J]. ANTIVIRAL RESEARCH, 1997, 36 (03) : 139 - 156
  • [5] Dolutegravir: First Global Approval
    Ballantyne, Anita D.
    Perry, Caroline M.
    [J]. DRUGS, 2013, 73 (14) : 1627 - 1637
  • [6] Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir
    Beck-Engeser, Gabriele B.
    Eilat, Dan
    Harrer, Thomas
    Jaeck, Hans-Martin
    Wabl, Matthias
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (49) : 20865 - 20870
  • [7] Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
    Castagna, Antonella
    Maggiolo, Franco
    Penco, Giovanni
    Wright, David
    Mills, Anthony
    Grossberg, Robert
    Molina, Jean-Michel
    Chas, Julie
    Durant, Jacques
    Moreno, Santiago
    Doroana, Manuela
    Ait-Khaled, Mounir
    Huang, Jenny
    Min, Sherene
    Song, Ivy
    Vavro, Cindy
    Nichols, Garrett
    Yeo, Jane M.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2014, 210 (03) : 354 - 362
  • [8] CRYSTAL-STRUCTURE OF THE CATALYTIC DOMAIN OF HIV-1 INTEGRASE - SIMILARITY TO OTHER POLYNUCLEOTIDYL TRANSFERASES
    DYDA, F
    HICKMAN, AB
    JENKINS, TM
    ENGELMAN, A
    CRAIGIE, R
    DAVIES, DR
    [J]. SCIENCE, 1994, 266 (5193) : 1981 - 1986
  • [9] HIV-1 DNA INTEGRATION - MECHANISM OF VIRAL-DNA CLEAVAGE AND DNA STRAND TRANSFER
    ENGELMAN, A
    MIZUUCHI, K
    CRAIGIE, R
    [J]. CELL, 1991, 67 (06) : 1211 - 1221
  • [10] Identification of two catalytic residues in RAG1 that define a single active site within the RAG1/RAG2 protein complex
    Fugmann, SD
    Villey, IJ
    Ptaszek, LM
    Schatz, DG
    [J]. MOLECULAR CELL, 2000, 5 (01) : 97 - 107